|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received January 3, 2002
Accepted after revision January 29, 2002
1 Division of Neurobiology, Department of Neurology and Neuroscience, Weill Medical College of Cornell University, 411 East 69th Street, New York, NY 10021, USA
2 INSERM-U432, Université Montpellier II, Montpellier F-34095, France
3 Department of Physiology and Neuroscience Program, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 016551, USA
4 Department of Physiology and Neuroscience Program, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA
* To whom correspondence should be addressed. E-mail: jose.lemos{at}umassmed.edu.
Effects of adenosine on voltage-gated Ca2+ channel currents and on arginine vasopressin (AVP) and oxytocin (OT) release from isolated neurohypophysial (NH) terminals of the rat were investigated using perforated-patch clamp recordings and hormone-specific radioimmunoassays. Adenosine, but not adenosine 5â-triphosphate (ATP), dose-dependently and reversibly inhibited the transient component of the whole-terminal Ba2+ currents, with an IC50 of 0.875 µM. Adenosine strongly inhibited, in a dose-dependent manner (IC50 = 2.67 µM), depolarization-triggered AVP and OT release from isolated NH terminals. Adenosine and the N-type Ca2+ channel blocker
-conotoxin GVIA, but not other Ca2+ channel-type antagonists, inhibited the same transient component of the Ba2+ current. Other components such as the L-, Q-, and R-type channels, however, were insensitive to adenosine. Adenosine and the N-type Ca2+ channel blocker
-conotoxin GVIA, but not other Ca2+ channel-type antagonists, inhibited the same component of AVP release. A1 receptor agonists, but not other purinoreceptor-type agonists, inhibited the same transient component of the Ba2+ current as adenosine. Furthermore, the A1 receptor antagonist 8-cyclopentyltheophylline (CPT), but not the A2 receptor antagonist 3, 7-dimethyl-1-propargylxanthine (DMPGX), reversed inhibition of this current component by adenosine. The inhibition of AVP and OT release also appeared to be via the A1-receptor, since it was reversed by CPT. We therefore conclude that adenosine, acting via A1 receptors, specifically blocks the terminal N-type Ca2+-channel thus leading to inhibition of the release of both AVP and OT.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |